BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

COO Franz-Werner Haas will become CureVac AG ’s permanent CEO, the mRNA vaccines company’s third this year. He has filled the role on an interim basis since mid-March. CEO Ingmar Hoerr took a leave of...
BioCentury | Aug 4, 2020
Finance

Interest in protein degradation runs hot as Kymera files for IPO

...such deals are likely to follow (see “More In Same Vein” ). Wound-healing matrix developer Acell Inc....
BioCentury | Jul 17, 2018
Distillery Therapeutics

Dermatology

INDICATION: Dermal ulcers Mouse studies suggest a laminin peptide-antioxidant conjugate could help treat diabetic foot ulcers. The conjugate consists of a 12-mer peptide derived from LAMA5, which interacts with CD49C/CD29 and other integrins to promote...
BioCentury | Sep 29, 2017
Strategy

Bridge to innovation

While Zai Lab Ltd. has joined the ranks of Chinese biotechs making a splash on NASDAQ, less noticed may be the first wave of China-based players moving into Boston to jump-start their push into novel...
BioCentury | Jun 30, 2017
Company News

Management tracks

Cell therapy play BlueRock Therapeutics (Toronto, Ontario) named Emile Nuwaysir president and CEO, and Robert Deans chief technology officer. Nuwaysir was president and COO at Cellular Dynamics International Inc. , which Fujifilm Holdings Corp. (Tokyo:4901) acquired...
BioCentury | May 8, 2017
Distillery Therapeutics

Dermatology

INDICATION: Wounds Patient sample and mouse studies suggest a topical hydrogel that scavenges MCP-1 , CCL3 , CCL4 and other inflammatory factors could help treat chronic wounds. The hydrogel consisted of star-shaped PEG (starPEG) and glycosaminoglycans containing...
BioCentury | Jan 6, 2017
Financial News

Acelity withdraws IPO

Acelity withdrew its IPO on NYSE, citing market conditions. Acelity filed for an IPO in August 2015. Acelity Holdings Inc. , San Antonio, Texas Alicia Parker Acelity Holdings Inc....
BioCentury | Oct 3, 2016
Finance

Reasonable rally

Steve Edelson, Senior Editor It looks like biotech's rebound will continue through the end of the year, but not with enough gusto to match the third quarter, or to make up for losses in the...
BioCentury | Sep 19, 2016
Financial News

Acelity completes venture financing

Acelity L.P. Inc. , San Antonio, Texas Business: Dermatology, Dental, Transplant Date completed: 2016-09-13 Type: Venture financing Raised: $1.8 billion Note: The financing comprises senior secured notes, which bear 9.625% interest and mature in 2021. The...
BioCentury | Sep 13, 2016
Company News

Management tracks

Gene therapy company NightstaRx Ltd. (London, U.K.) named Gregory Robinson CSO. He was CSO at Agilis Biotherapeutics LLC (Cambridge, Mass.). Wound care company Acelity L.P. Inc. (San Antonio, Texas) said EVP and CFO Tom Casey...
Items per page:
1 - 10 of 125
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

COO Franz-Werner Haas will become CureVac AG ’s permanent CEO, the mRNA vaccines company’s third this year. He has filled the role on an interim basis since mid-March. CEO Ingmar Hoerr took a leave of...
BioCentury | Aug 4, 2020
Finance

Interest in protein degradation runs hot as Kymera files for IPO

...such deals are likely to follow (see “More In Same Vein” ). Wound-healing matrix developer Acell Inc....
BioCentury | Jul 17, 2018
Distillery Therapeutics

Dermatology

INDICATION: Dermal ulcers Mouse studies suggest a laminin peptide-antioxidant conjugate could help treat diabetic foot ulcers. The conjugate consists of a 12-mer peptide derived from LAMA5, which interacts with CD49C/CD29 and other integrins to promote...
BioCentury | Sep 29, 2017
Strategy

Bridge to innovation

While Zai Lab Ltd. has joined the ranks of Chinese biotechs making a splash on NASDAQ, less noticed may be the first wave of China-based players moving into Boston to jump-start their push into novel...
BioCentury | Jun 30, 2017
Company News

Management tracks

Cell therapy play BlueRock Therapeutics (Toronto, Ontario) named Emile Nuwaysir president and CEO, and Robert Deans chief technology officer. Nuwaysir was president and COO at Cellular Dynamics International Inc. , which Fujifilm Holdings Corp. (Tokyo:4901) acquired...
BioCentury | May 8, 2017
Distillery Therapeutics

Dermatology

INDICATION: Wounds Patient sample and mouse studies suggest a topical hydrogel that scavenges MCP-1 , CCL3 , CCL4 and other inflammatory factors could help treat chronic wounds. The hydrogel consisted of star-shaped PEG (starPEG) and glycosaminoglycans containing...
BioCentury | Jan 6, 2017
Financial News

Acelity withdraws IPO

Acelity withdrew its IPO on NYSE, citing market conditions. Acelity filed for an IPO in August 2015. Acelity Holdings Inc. , San Antonio, Texas Alicia Parker Acelity Holdings Inc....
BioCentury | Oct 3, 2016
Finance

Reasonable rally

Steve Edelson, Senior Editor It looks like biotech's rebound will continue through the end of the year, but not with enough gusto to match the third quarter, or to make up for losses in the...
BioCentury | Sep 19, 2016
Financial News

Acelity completes venture financing

Acelity L.P. Inc. , San Antonio, Texas Business: Dermatology, Dental, Transplant Date completed: 2016-09-13 Type: Venture financing Raised: $1.8 billion Note: The financing comprises senior secured notes, which bear 9.625% interest and mature in 2021. The...
BioCentury | Sep 13, 2016
Company News

Management tracks

Gene therapy company NightstaRx Ltd. (London, U.K.) named Gregory Robinson CSO. He was CSO at Agilis Biotherapeutics LLC (Cambridge, Mass.). Wound care company Acelity L.P. Inc. (San Antonio, Texas) said EVP and CFO Tom Casey...
Items per page:
1 - 10 of 125